Profile of renal AA amyloidosis in older and younger individuals: a single-centre experience

References

• Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17:3458–3471.
   PubMed Web of Science ®Google Scholar
• Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012;142:w13580.
   PubMed Web of Science ®Google Scholar
• Real de Asúa D, Costa R, Galván JM, et al. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–377.
   PubMed Web of Science ®Google Scholar
• Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999;31:619–631.
   PubMedGoogle Scholar
• Tuglular S, Yalcinkaya F, Paydas S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant. 2002;17:2003–2005.
   PubMed Web of Science ®Google Scholar
• Ensari C, Ensari A, Tümer N, et al. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant. 2005;20:1721–1725.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Unsal A, Sokmen M, et al. Renal involvement in AA amyloidosis: clinical outcomes and survival. Kidney Blood Press Res. 2013;37:33–42.
   PubMed Web of Science ®Google Scholar
• Ahbap E, Kara E, Sahutoglu T, et al. Outcome of 121 patients with renal amyloid a amyloidosis. J Res Med Sci. 2014;19:644–649.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879–1885.
   PubMed Web of Science ®Google Scholar
• Joss N, McLaughlin K, Simpson K, et al. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000;93:535–542.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–29.
   PubMed Web of Science ®Google Scholar
• Verine J, Mourad N, Desseaux K, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol. 2007;38:1798–1809.
   PubMed Web of Science ®Google Scholar
• Esteve V, Almirall J, Ponz E, et al. Renal involvement in amyloidosis. Clinical outcomes, evolution and survival. Nefrologia. 2006;26:212–217.
   PubMed Web of Science ®Google Scholar
• Bergesio F, Ciciani AM, Santostefano M, Immunopathology Group, Italian Society of Nephrology, et al. Renal involvement in systemic amyloidosis–an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22:1608–1618.
   PubMed Web of Science ®Google Scholar
• Girnius S, Dember L, Doros G, et al. The changing face of AA amyloidosis: a single center experience. Amyloid. 2011;18:226–228.
   PubMed Web of Science ®Google Scholar
• Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997–2012. Mt Sinai J Med. 2012;79:749–756.
   PubMedGoogle Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371.
   PubMed Web of Science ®Google Scholar
• Touitou I, Sarkisian T, Medlej-Hashim M, International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56:1706–1712.
   PubMed Web of Science ®Google Scholar
• Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol. 1999;18:122–123.
   PubMed Web of Science ®Google Scholar
• Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525–532.
   PubMed Web of Science ®Google Scholar
• Panizo N, Rivera F, López-Gómez JM. Spanish Registry of Glomerulonephritis. Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest. 2013;43:767–773.
   PubMed Web of Science ®Google Scholar
• Lane T, Pinney JH, Gilbertson JA, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid. 2017;24:162–166.
   PubMed Web of Science ®Google Scholar
• Akse-Onal V, Sağ E, Ozen S, et al. Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better? Eur J Pediatr. 2010;169:971–974.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–256.
   PubMed Web of Science ®Google Scholar
• Bergesio F, Ciciani AM, Manganaro M, Immunopathology Group of the Italian Society of Nephrology, et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant. 2008;23:941–951.
   PubMed Web of Science ®Google Scholar
• Kendi Celebi Z, Kiremitci S, Ozturk B, et al. Kidney biopsy in AA amyloidosis: impact of histopathology on prognosis. Amyloid. 2017;24:176–182.
   PubMed Web of Science ®Google Scholar